Schedule 13D ownership disclosure

CHEMOMAB THERAPEUTICS LTD

Ordinary Shares, no par value. American Depository Shares, each of which represents twenty Ordinary Shares, no par value · CUSIP: 16385C104

Event date: 2025-06-18

Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.

Filing-level shares
Unavailable
Percent of class
Unavailable
  • ORBIMED ISRAEL BIOFUND GP LIMITED PARTNERSHIPReported CIK 0001569821

    Shares: 969,807.00 · Class: 4.8%

  • ORBIMED ISRAEL GP LTD.Reported CIK 0001569590

    Shares: 969,807.00 · Class: 4.8%

  • CHIMOVITS EREZReported CIK 0001706399

    Shares: 969,807.00 · Class: 4.8%

  • GORDON CARL LReported CIK 0001282930

    Shares: 969,807.00 · Class: 4.8%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0000947871-25-000624
Form type
SCHEDULE 13D/A
Filer
Chemomab Therapeutics Ltd.
CIK
CIK 1534248
Filed
Jun 23, 2025
Reporting period
Jun 18, 2025
Description
Schedule 13D beneficial ownership

Explore SEC Filings Hub